Clinical Trial Update: AK129 Combination Therapy for Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

AK129 is being studied in Phase 1/2 trials for multiple advanced solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• AK129 (anti-PD-1 and LAG-3 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1, Phase 2 | Status: RECRUITING